Calendario›REGN›CMP-001

CMP-001

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

Ensayo de REGENERON PHARMACEUTICALS, INC. en Melanoma.

Más ensayos de: Melanoma.

Fase

Fase 1

Estado

Completado

Participantes

199

previstos

Centros

13

Fin del objetivo primario

dic 2022

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en abr 2016.

Qué mide

Part 1: Dose-Escalation Phase: RP2D of CMP-001 When Given in Combination With Pembrolizumab (21 days (for Schedule A dosing) and 35 days (for Schedule B dosing)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available to those who are currently being treated in either Part 1 or Part 2 of this study at the time of protocol Amendment 9, v10.0.

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02680184), actualizada en jul 2025.